Skip to content
10-Q

Quarterly Report

Actinium Pharmaceuticals, Inc. ATNM

0001213900-25-041614

← back to feed
Filed
May 9, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 31.2M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $65.33M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $72.9M
Current Liabilities Q1 2025 · Mar 31, 2025 $7.11M
Current Liabilities Q1 2025 · Dec 31, 2024 $8.15M
Total Liabilities Q1 2025 · Mar 31, 2025 $42.95M
Total Liabilities Q1 2025 · Dec 31, 2024 $44.14M
Current Assets Q1 2025 · Mar 31, 2025 $66.46M
Current Assets Q1 2025 · Dec 31, 2024 $74.51M
Total Assets Q1 2025 · Mar 31, 2025 $68.65M
Total Assets Q1 2025 · Dec 31, 2024 $76.9M
Shares Diluted Q1 2025 · Mar 31, 2024 27.89M sh
Capex Q1 2025 · Mar 31, 2024 $11K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$7.37M
Stockholders Equity Q1 2025 · Mar 31, 2024 $43.86M
Stockholders Equity Q1 2025 · Dec 31, 2023 $36.38M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.31
Eps Basic Q1 2025 · Mar 31, 2024 −$0.31
Sga Expense Q1 2025 · Mar 31, 2024 $2.96M
Rd Expense Q1 2025 · Mar 31, 2024 $6.64M
Net Income Q1 2025 · Mar 31, 2024 −$8.67M
Operating Income Q1 2025 · Mar 31, 2024 −$9.6M